Drotrecogin alfa - Eli Lilly
Alternative Names: Activated-protein-C; Activated-protein-C - Eli-Lilly; DrotAA; Drotrecogin-alfa-activated; Drotrecogin-alpha; LTC-203; LY 203638; Recombinant human activated protein C; rhAPC; XigrisLatest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Developer Georgetown University; Syncor; Teijin Pharma
- Class Anticoagulants; Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins
- Mechanism of Action Fibrinolytic agents; Serine endopeptidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Septic shock
- Discontinued Thrombosis
Most Recent Events
- 25 Oct 2011 Discontinued - Phase-I for Septic shock in Japan (IV)
- 25 Oct 2011 Discontinued - Registered for Septic shock in Colombia (IV)
- 25 Oct 2011 Discontinued - Registered for Septic shock in Peru (IV)